vs
Side-by-side financial comparison of Dexcom (DXCM) and Evercore Inc. (EVR). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.4B vs $1.3B, roughly 1.1× Dexcom). Evercore Inc. runs the higher net margin — 23.0% vs 21.2%, a 1.8% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 21.6%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 12.0%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
DXCM vs EVR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.4B |
| Net Profit | $267.3M | $322.7M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | — |
| Net Margin | 21.2% | 23.0% |
| Revenue YoY | 21.6% | 100.3% |
| Net Profit YoY | 153.6% | 106.1% |
| EPS (diluted) | $0.67 | $7.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $1.4B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.2B | $1.0B | ||
| Q2 25 | $1.2B | $838.0M | ||
| Q1 25 | $1.0B | $699.0M | ||
| Q4 24 | $1.1B | $979.5M | ||
| Q3 24 | $994.2M | $738.4M | ||
| Q2 24 | $1.0B | $693.4M |
| Q1 26 | $267.3M | $322.7M | ||
| Q4 25 | $267.3M | $204.0M | ||
| Q3 25 | $283.8M | $144.6M | ||
| Q2 25 | $179.8M | $97.2M | ||
| Q1 25 | $105.4M | $146.2M | ||
| Q4 24 | $151.7M | $140.4M | ||
| Q3 24 | $134.6M | $78.4M | ||
| Q2 24 | $143.5M | $73.8M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 24.2% | ||
| Q3 25 | 20.1% | 20.8% | ||
| Q2 25 | 18.4% | 18.0% | ||
| Q1 25 | 12.9% | 16.0% | ||
| Q4 24 | 17.0% | 21.8% | ||
| Q3 24 | 15.3% | 16.7% | ||
| Q2 24 | 15.7% | 15.9% |
| Q1 26 | 21.2% | 23.0% | ||
| Q4 25 | 21.2% | 15.7% | ||
| Q3 25 | 23.5% | 13.8% | ||
| Q2 25 | 15.5% | 11.6% | ||
| Q1 25 | 10.2% | 20.9% | ||
| Q4 24 | 13.6% | 14.3% | ||
| Q3 24 | 13.5% | 10.6% | ||
| Q2 24 | 14.3% | 10.6% |
| Q1 26 | $0.67 | $7.20 | ||
| Q4 25 | $0.67 | $4.80 | ||
| Q3 25 | $0.70 | $3.41 | ||
| Q2 25 | $0.45 | $2.36 | ||
| Q1 25 | $0.27 | $3.48 | ||
| Q4 24 | $0.37 | $3.32 | ||
| Q3 24 | $0.34 | $1.86 | ||
| Q2 24 | $0.35 | $1.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | — |
| Total Assets | $6.3B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $3.0B | ||
| Q3 25 | $1.8B | $2.4B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $904.9M | $1.4B | ||
| Q4 24 | $606.1M | $2.4B | ||
| Q3 24 | $621.2M | $1.8B | ||
| Q2 24 | $939.2M | $1.7B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $2.0B | ||
| Q3 25 | $2.7B | $1.8B | ||
| Q2 25 | $2.6B | $1.7B | ||
| Q1 25 | $2.3B | $1.5B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.0B | $1.6B | ||
| Q2 24 | $2.4B | $1.5B |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $5.4B | ||
| Q3 25 | $7.5B | $4.4B | ||
| Q2 25 | $7.3B | $3.7B | ||
| Q1 25 | $6.8B | $3.3B | ||
| Q4 24 | $6.5B | $4.2B | ||
| Q3 24 | $6.4B | $3.6B | ||
| Q2 24 | $6.8B | $3.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
